tetano
Editor, Senior Moderator
Clin Respir J. 2014 Mar 10. doi: 10.1111/crj.12129. [Epub ahead of print]
Clinical Efficacy of Peramivir in Adult Patients with Seasonal Influenza during the winter of 2012 in Japan.
Yoshino Y1, Seo K, Koga I, Kitazawa T, Ota Y.
Author information
Abstract
BACKGROUND:
Peramivir is an intravenously administered neuraminidase inhibitor for influenza. The clinical efficacy of peramivir remains unclear, because it is used in a limited number of countries. We compared the clinical efficacy of peramivir with that of oseltamivir in influenza patients during the 2012-2013 season.
METHODS:
Thirty-two influenza patients who were hospitalized at Teikyo University Hospital, a teaching hospital in Tokyo, Japan, from October 2012 to March 2013 were enrolled. Among them, 23 and 9 were treated with peramivir and oseltamivir, respectively. The endpoints of this study were the time to defervescence and survival rate.
RESULTS:
There were no significant differences in the clinical backgrounds of the 2 groups. However, patients treated with peramivir tended to have a higher incidence of consciousness disturbance [34.8% (8/23) vs. 0.00% (0/9), p = 0.06]. There were no significant differences between the peramivir and oseltamivir groups with respect to the time to defervescence (30.9 ? 18.7 hours vs. 34.7 ? 18.6 hours) or survival rate [95.7% (22/23) vs. 100% (9/9), respectively].
CONCLUSIONS:
The clinical efficacy of peramivir is noninferior to that of oseltamivir, although peramivir tended to be used in patients with serious complications. Intravenous administration of peramivir may be useful for patients with serious complications such as consciousness disturbances.
This article is protected by copyright. All rights reserved.
KEYWORDS:
Clinical efficacy, Influenza, Oseltamivir, Peramivir
PMID:
24612842
[PubMed - as supplied by publisher]
http://www.ncbi.nlm.nih.gov/pubmed/24612842
Clinical Efficacy of Peramivir in Adult Patients with Seasonal Influenza during the winter of 2012 in Japan.
Yoshino Y1, Seo K, Koga I, Kitazawa T, Ota Y.
Author information
Abstract
BACKGROUND:
Peramivir is an intravenously administered neuraminidase inhibitor for influenza. The clinical efficacy of peramivir remains unclear, because it is used in a limited number of countries. We compared the clinical efficacy of peramivir with that of oseltamivir in influenza patients during the 2012-2013 season.
METHODS:
Thirty-two influenza patients who were hospitalized at Teikyo University Hospital, a teaching hospital in Tokyo, Japan, from October 2012 to March 2013 were enrolled. Among them, 23 and 9 were treated with peramivir and oseltamivir, respectively. The endpoints of this study were the time to defervescence and survival rate.
RESULTS:
There were no significant differences in the clinical backgrounds of the 2 groups. However, patients treated with peramivir tended to have a higher incidence of consciousness disturbance [34.8% (8/23) vs. 0.00% (0/9), p = 0.06]. There were no significant differences between the peramivir and oseltamivir groups with respect to the time to defervescence (30.9 ? 18.7 hours vs. 34.7 ? 18.6 hours) or survival rate [95.7% (22/23) vs. 100% (9/9), respectively].
CONCLUSIONS:
The clinical efficacy of peramivir is noninferior to that of oseltamivir, although peramivir tended to be used in patients with serious complications. Intravenous administration of peramivir may be useful for patients with serious complications such as consciousness disturbances.
This article is protected by copyright. All rights reserved.
KEYWORDS:
Clinical efficacy, Influenza, Oseltamivir, Peramivir
PMID:
24612842
[PubMed - as supplied by publisher]
http://www.ncbi.nlm.nih.gov/pubmed/24612842